Skip to main content

Lamivudine News

Swift Use of Antiretrovirals in Infected Newborns Can Banish HIV

MONDAY, Dec. 11, 2023 – When an HIV-infected child known as the 'Mississippi baby' was given powerful antiretroviral drugs within hours of birth in 2013 and then appeared to be rid of HIV, people...

Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.

HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ – Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV...

Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.

HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ – Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV...

FDA Approves Dutrebis (lamivudine and raltegravir) for HIV-1 Infection

February 6, 2015 – The United States Food and Drug Administration (FDA) has approved Dutrebis, a fixed dose combination tablet containing 150 mg of lamivudine and 300 mg of raltegravir. Dutrebis...

FDA Approves Triumeq for the Treatment of HIV-1 Infection

August 22, 2014 – ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

HIV Infection

Lamivudine patient information at Drugs.com